Results 121 to 130 of about 326,843 (184)

Hepatitis B and D burden in Uzbekistan: comprehensive analysis of seroprevalence and risk correlates from a countrywide study. [PDF]

Infect Dis Poverty
Musabaev EI, Khodjaeva ME, Khikmatullaeva AS, Ibadullaeva NS, Shodieva FSK, Khudaykulova GK, Tadjieva NU, Amonov SB, Mirzaev UK.   +8 more
europepmc   +1 more source

Virologic Response to Antiviral Therapy in Chronic Hepatitis B Patients With High Viral Load: A Real-World Cohort Study. [PDF]

J Viral Hepat
Zheng S, Li X, Liu H, Mao T, Ge Y, Ji W, Wang X, Bao Y, Zhang Y, Zhou A, Danzeng Q, Wang J, Yang F, Xiong Q, Yang Y.   +14 more
europepmc   +1 more source

Serological Profile of Hepatitis B, C, and D and Factors Associated With Hepatitis B Exposure and Vaccination Among Hemodialysis Patients in Northeastern Brazil. [PDF]

Int J Nephrol
da Silva LL, Mota JC, Dos Santos AC, da Costa VD, do Nascimento GP, Marques JT, Miguel JC, Liborio AB, Lima DM, Colares JKB, de Paula VS, Villar LM.   +11 more
europepmc   +1 more source

Occult Hepatic Pathology in Medicolegal Autopsies: A Single-Center Histopathological Study From Jharkhand, India. [PDF]

Cureus
Biswal SDR, Paswan MK, Jamaiyar A.
europepmc   +1 more source

Pharmacological Potential of Selenoproteins in the Regulation of Oxidative Stress in Liver Diseases. [PDF]

Pharmaceutics
Varlamova EG.
europepmc   +1 more source

Frequency of Hepatitis B and Hepatitis C Infections Among Patients With Chronic Kidney Disease: A Retrospective Data-Based Study From Lahore, Pakistan. [PDF]

Cureus
Sami MT, Liaqat A, Latif MT, Akram N, Sami A, Butt NI.   +5 more
europepmc   +1 more source

Attendance Among People With Hepatitis B in UK Secondary Care: A Scoping Review. [PDF]

J Viral Hepat
Shiel EV, George B, Verma A, Gasteiger N.   +3 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Chronic hepatic porphyria in chronic aggressive hepatitis

Klinische Wochenschrift, 1971
An acquired (“symptomatic”) chronic hepatic porphyria (CHP) is described, which develops secondarily following damage to the liver tissue and is characterized by the absence of clinical symptoms. It can be differentiated biochemically from latent porphyria cutanea tarda (PCT) by a lower total porphyrin excretion (0.18–0.64 mg/l) and a relatively ...
M, Doss, D, Look, H, Henning
openaire   +2 more sources